More Is Needed for Immunotherapy in Lung Cancer


From long-term data to additional clinical trials, more is needed to better understand immunotherapy in lung cancer.

Immunotherapy generated landmark change in the treatment of lung cancer, but there are still some pressing issues and unanswered questions that need to be addressed, according to Fred R. Hirsch, MD, PhD, executive director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.


Well immunotherapy is encouraging, but still we need a lot of work to improve the long-term effects. Even if we have very impressive, most recent 5-year survival data for monotherapy, and it might be even better with combination therapy, but what is the best combination? What is the sequencing of the combination? That is an area we need to work on in the future.

We need solid clinical trials. We need to be sure we get biopsies from the patients before and after treatment to learn about sensitive mechanisms and resistant mechanisms. As I mentioned before, it is also in the future, important, in that case, it would be liquid biopsies during treatment to see if we can monitor the changes over time.

Read more: Frontline Lung Cancer Treatment: What's the Best Strategy?

Improving Immunotherapy Implementation in Community Practice

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.